# Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

> **NCT00129259** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 83 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** Anti-CD3 mAb
- **OTHER:** Diabetes Standard of Care Treatment
- **DIETARY_SUPPLEMENT:** Iron supplementation

## Key facts

- **NCT ID:** NCT00129259
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2017-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129259, "Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00129259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*